Glycosaminoglycan and chemokine/growth factor interactions

Handbook of Experimental Pharmacology

Volumn 207, Issue , 2012, Pages 307-324

  Shute, Janis ^a  

^a UNIVERSITY OF PORTSMOUTH   (United Kingdom)

Author keywords

Chemokine; Glycosaminoglycan; Growth factor; Therapeutic intervention

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; FIBROBLAST GROWTH FACTOR; GLYCOSAMINOGLYCAN; GROWTH FACTOR; HEPARAN SULFATE; HEPARIN; INTERLEUKIN 8; RANTES; SCATTER FACTOR; STROMAL CELL DERIVED FACTOR 1; SYNDECAN 1; THROMBOCYTE FACTOR 4; VASCULOTROPIN; SIGNAL PEPTIDE;

ALLERGIC ENCEPHALOMYELITIS; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BASEMENT MEMBRANE; CELL PROLIFERATION; COMPLEX FORMATION; ENDOTHELIUM CELL; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; IMMUNE RESPONSE; LEUKOCYTE ACTIVATION; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN ENGINEERING; PROTEIN PROTEIN INTERACTION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOSIS; TISSUE REGENERATION; VASCULAR ENDOTHELIUM; METABOLISM; REVIEW;

CHEMOKINES; GLYCOSAMINOGLYCANS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS;

EID: 84861878700     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-642-23056-1_13     Document Type: Article

References (76)

1. AlexopoulouAN, MulthauptHAB, Couchman JR (2007) Syndecans in wound healing, inflammation and vascular biology. Int J Biochem Cell Biol 39:505-528
2. Bedke J, Nelson PJ, Kiss E et al (2010) A novel CXCL8 protein-based antagonist in acute experimental renal allograft damage. Mol Immunol 47(5):1047-1057
3. Beenken A, Mohammadi M (2009) The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 8:235-253
4. Belpeiro JA, Keane MP, Arenberg DA et al (2000) CXC chemokines in angiogenesis. J Leukoc Biol 68:1-8
5. Birchmeier C, Birchmeier W, Gheradi E, van de Woude GF (2003) MET, metastasis, motility and more. Nat Rev Mol Cell Biol 4:915-925
6. Bishop JR, Schuksz M, Esko JD (2007) Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 446:1030-1037
7. Brandner B, Rek A, Diedrichs-Mohring M et al (2009) Engineering the glycosaminoglycanbinding affinity, kinetics and oligomerization behaviour of RANTES: A tool for generating chemokine-based glycosaminoglycan antagonists. Prot Eng Des Select 22:367-373
8. Brandt E, Ludwig A, Petersen F, Flad H-D (2000) Platelet-derived CXC chemokines: Old players in new games. Immunol Rev 177:204-216
9. Capila I, Linhardt RJ (2002) Heparin-protein interaction. Angew Chem Int Ed Engl 41:390-412
10. Catlow KR, Deakin JA, Wei Z et al (2008) Interactions of hepatocyte growth factor/scatter factor with various glycosaminoglycans reveal an important interplay between the presence of iduronate and sulphate density. J Biol Chem 283:5235-5248
11. Charnaux N, Brule S, Hamon M et al (2005) Syndecan-4 is a signalling molecule for stromal cell-derived factor-1 (SDF-1)/CXCL12. FEBS J 272:1937-1951
12. Charni F, Friand V, Haddad O et al (2009) Syndecan-1 and syndecan-4 are involved in RANTES/CCL5-induced migration and invasion of human hepatoma cells. Biochim Biophys Acta 1790:1314-1326
13. Colditz IG, Schneider MA, Pruenster M, Rot A (2007) Chemokines at large: in-vivo mechanisms of their transport, presentation and clearance. Thromb Haemost 97:688-693
14. De Larco JE, Wuertz BRK, Furcht LT (2004) The potential role of neutrophils in promoting the metastatic phenotype of tumours releasing interleukin-8. Clin Cancer Res 10:4895-4900
15. De Paz JL, Moseman EA, Noti C et al (2007) Profiling heparan-chemokine interactions using synthetic tools. ACS Chem Biol 2:735-744
16. Ferro V, Dredge K, Liu L et al (2007) PI-88 and novel heparan sulphate mimetics inhibit angiogenesis. Semin Thromb Hemost 33:557-568
17. Freeman C, Liu L, Banwell MG et al (2005) Use of sulphated linked cyclitols as heparan sulphate mimetics to probe the heparin/heparan sulphate binding specificity of proteins. J Biol Chem 280:8842-8849
18. Frevert CW, Kinsella MG, Vathanaprida C et al (2003) Binding of interleukin-8 to heparan sulfate and chondroitin sulfate in lung tissue. Am J Respir Cell Mol Biol 28:464-472
19. Gallagher JT (2006) Multiprotein signalling complexes: regional assembly on heparan sulphate. Biochem Soc Trans 34:438-441
20. Gandhi NS, Mancera RL (2008) The structure of glycosaminoglycans and their interactions with proteins. Chem Biol Drug Des 72:455-482
21. Gleissner CA, von Hundelhausen P, Ley K (2008) Platelet chemokines in vascular disease. Arterioscler Thromb Vasc Biol 28:1920-1927
22. Goodger SJ, Robinson CJ, Murphy KJ et al (2008) Evidence that heparin saccharides promote FGF2 mitogenesis through two distinct mechanisms. J Biol Chem 283:13001-13008
23. Greinacher A (2009) Heparin-induced thrombocytopenia. J Thromb Haemost 7:9-12
24. Halden Y, Rek A, Atzenhofer W et al (2004) Interleukin-8 binds to syndecan-2 on human endothelial cells. Biochem J 377:533-538
25. Handel TM, Johnson Z, Crown SE et al (2005) Regulation of protein function by glycosaminoglycans - as exmplified by chemokines. Annu Rev Biochem 74:385-410
26. Harmer NJ (2006) Insights into the role of heparan sulphate in fibroblast growth factor signalling. Biochem Soc Trans 34:442-445
27. Hoogewerf AJ, Kushert GSV, Proudfoot AEI et al (1997) Glycosaminoglycans mediate cell surface oligomerisation of chemokines. Biochemistry 36:13570-13578
28. Johnson Z, Kosco-Vilbois MH, Herren S et al (2004) Interference with heparin binding and oligomerisation creates a novel anti-inflammatory strategy targeting the chemokine system. J Immunol 173:5776-5785
29. Joung YK, Bae JW, Park KD (2008) Controlled release of heparin-binding growth factors using heparin-containing particulate systems for tissue regeneration. Expert Opin Drug Deliv 5: 1173-1184
30. Kato M, Wang H, Kainulainen V et al (1998) Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2. Nat Med 4:691-697
31. Khachigian LM, Parish CR (2004) Phosphomannopentaose sulphate (PI-88): heparan sulphate mimetic with clinical potential in multiple vascular pathologies. Cardiovasc Drug Rev 22:1-6
32. Kreuger J, Spillman D, Li J-P, Lindahl U (2006) Interactions between heparan sulfate and proteins: the concept of specificity. J Cell Biol 174:323-327
33. Kuschert GS, Hoogewerf AJ, Proudfoot AE et al (1998) Identification of a glycosaminoglycan binding surface on human interleukin-8. Biochemistry 37:11193-11201
34. Kuschert GSV, Coulin F, Power CA et al (1999) Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses. Biochemistry 38: 12959-12968
35. Ley K, Laudanna C, Cybulsky MI, Nourshargh S (2007) Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 7:678-689
36. Li Q, Park PW, Wilson CL, Parks WC (2002) Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell 111:635-646
37. Lortat-Jacob H (2009) The molecular basis and functional implications of chemokine interactions with heparan sulphate. Curr Opin Struct Biol 19:543-548
38. Lortat-Jacob H, Grosdidier A, Imberty A (2002) Structural diversity of heparan sulphate binding domains in chemokines. Proc Natl Acad Sci USA 99:1229-1234
39. Malavaki C, Mizumoto N, Karamanos N, Sugahara K (2008) Recent advances in the structural study of functional chondroitin and dermatan sulphate in health and disease. Conn Tiss Res 49:133-139
40. Marshall LJ, Ramdin LS, Brooks T et al (2003) Plasminogen activator inhibitor-1 supports IL- 8-mediated neutrophil transendothelial migration by inhibition of the constitutive shedding of endothelial IL-8/heparan sulfate/syndecan-1 complexes. J Immunol 171:2057-65
41. Martin L, Blanpain C, Garnier P et al (2001) Structural and functional analysis of the RANTESglycosaminoglycans interactions. Biochemistry 40:6303-6318
42. Masouleh BK, Ten Dam GB, Wild MK et al (2009) Role of heparan sulphate proteoglycan syndecan-1 (CD138) in delayed type hypersensitivity. J Immunol 182:4985-4993
43. Mikhailov D, Young HC, Linhardt RJ, Mayo KH (1999) Heparin dodecasaccaride binding to platelet factor-4 and growth-related protein-alpha. Induction of a partially folded state and implications for heparin-induced thrombocytopenia. J Biol Chem 274:25317-25329
44. Murphy JW, Cho Y, Sachpatzidis A et al (2007) Structural and functional basis of CXCL12 (stromal cell-derived factor-1 alpha) binding to heparin. J Biol Chem 282:10018-10027
45. Nickel W (2007) Unconventional secretion: An extracellular trap for export of fibroblast growth factor 2. J Cell Sci 120:2295-2299
46. Parish CR (2006) The role of heparan sulphate in inflammation. Nat Rev Immunol 6:633-643
47. Patterson AM, Gardner L, Shaw J et al (2005) Induction of a CXCL8 binding site on endothelial syndecan-3 in rheumatoid synovium. Arthritis Rheum 52:2331-2342
48. Poncz M (2005) Mechanistic basis of heparin-induced thrombocytopenia. Semin Thorac Cardiovasc Surg 17:73-79
49. Proudfoot AE, Fritchley S, Borlat F et al (2001) The BBXB motif of RANTES is the principal site for heparin binding and controls receptor selectivity. J Biol Chem 276:10620-10626
50. Proudfoot AE, Handel TM, Johnson Z et al (2003) Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc Natl Acad Sci USA 100:1885-1890
51. Proudfoot AEI, de Souza ALS, Muzio V (2008) The use of chemokine antagonists in EAE models. J Neuroimmunol 198:27-30
52. Rajarathnam K, Sykes BD, Kay CM et al (1994) Neutrophil activation by monomeric interleukin- 8. Science 264:90-92
53. Ramdin L, Perks B, Sheron N, Shute JK (1997) Regulation of interleukin-8 binding and function by heparin and alpha2-macroglobulin. Clin Exp Allergy 28:616-624
54. Rek A, Brandner B, Geretti E, Kungl AJ (2009a) A biophysical insight into the RANTESglycoaminoglycan interaction. Biochim Biophys Acta 1794:577-582
55. Rek A, Krenn E, Kungl AJ (2009b) Therapeutically targeting protein-glycan interactions. Br J Pharmacol 157:686-694
56. Robinson CJ, Mulloy B, Gallagher JT, Stringer SE (2006) VEGF165-binding sites within heparan sulphate encompass two highly sulphated domains and can be liberated by K5 lyase. J Biol Chem 281:1731-1740
57. Rot A (1992) Endothelial cell binding of NAP-1/IL-8: role in neutrophil emigration. Immunol Today 13:291-294
58. Rot A, Hub E, Middleton J et al (1996) Some aspects of IL-8 pathophysiology III: Chemokine interaction with endothelial cells. J Lukoc Biol 59:39-44
59. Rueda P, Balabanian K, Lagane B et al (2008) The CXCL12g chemokine displays unprecedented structural ad functional properties that make it a paradigm of chemoattractant proteins. PLoS One 3:e2543
60. Ruhrberg C (2003) Growing and shaping the vascular tree: multiple roles for VEGF. Bioessays 25:1052-1060
61. Schuksz M, Fuster MM, Brown JR et al (2008) Surfen, a small molecule antagonist of heparan sulphate. Proc Natl Acad Sci USA 105:13075-13080
62. Segerer S, Johnson Z, Rek A et al (2009) The basic residue cluster 55KKWVR59 in CCL5 is required for in vivo biologic function. Mol Immunol 46:2533-2538
63. Shamri R, Grabovsky V, Gauguet JM et al (2005) Lymphocyte arrest requires instantaneous induction of an extended LFA-1 conformation mediated by endothelium-bound chemokines. Nat Immunol 6:497-506
64. Solic N, Wilson J, Wilson SJ, Shute JK (2005) Endothelial activation and increased heparan sulfate expression in cystic fibrosis. Am J Respir Crit Care Med 72:892-898
65. Spillman D, Witt D, Lindahl U (1998) Defining the interleukin-8 binding domain of heparan sulphate. J Biol Chem 273:15487-15493
66. Stringer SE, Gallagher JT (1997) Specific binding of the chemokine platelet factor 4 to heparan sulphate. J Biol Chem 272:20508-20514
67. Sutton A, Friand V, Papy-Garcia D et al (2007) Glycosaminoglycans and their synthetic mimetics inhibit RANTES-induced migration and invasion of human hepatoma cells. Mol Cancer Ther 6:2948-2958
68. Taipale J, Keski-Oja J (1997) Growth factors in the extracellular matrix. FASEB J 11:51-59
69. Wagner L, Yang OO, Garcia-Zepeda EA et al (1998) Beta-chemokines are released from HIV- 1-specific cytolytic T-cell granules complexed to proteoglycans. Nature 391(6670):908-911
70. Wang L, Fuster M, Sriramarao P, Esko JD (2005) Endothelial heparan sulphate deficiency impairs L-selectin- and chemokine-mediated neutrophil trafficking during inflammatory responses. Nat Immunol 6:902-910
71. Waugh DJJ, Wilson C (2008) The interleukin-8 pathway in cancer. Clin Cancer Res 14:6735-6741
72. Xiao Z, Visentin GP, Dayananda K, Neelamegham S (2008) Immune complexes formed following the binding of anti-platelet factor 4 (CXCL4) antibodies to CXCL4 stimulate human neutrophil activation and cell adhesion. Blood 112:1091-1100
73. Xu J, Park PW, Kheradmand F, Corry DB (2005) Endogenous attenuation of allergic lung inflammation by syndecan-1. J Immunol 174:5758-5765
74. Yamaguchi K, Tamaki H, Fukui S (2006) Detection of oligosaccharide ligands for hepatocyte growth factor/scatter factor (HGF/SF), keratinocyte growth factor (KGF/FGF-7), RANTES and heparin cofactor II by neoglycolipid microarrays of glycosaminoglycan-derived oligosaccharide fragments. Glycoconj J 23:513-523
75. Yoshimura T, Matsushima K, Tanaka S et al (1987) Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host-defense cytokines. Proc Natl Acad Sci USA 84:9233-9237
76. Zlotnik A, Yoshie O, Nomiyama H (2006) The chemokine and chemokine receptor superfamilies and their molecular evolution. Genome Biol 7:243